Atopic eczema affects 1 in 5 children in the UK and for years nothing other than emollients, steroid creams and immunosuppressants have been available.
In the latest randomized, placebo-controlled, double-blind, parallel-group study recruited 251 adolescents aged 12 to 17 years old (mean age: 14 years) with moderate-to-severe atopic dermatitis that was inadequately controlled by topical therapies. This study looked at Dupilumab treatment for eczema and the results showed clinically meaningful and statistically significant improvements in atopic dermatitis signs and symptoms and quality of life in adolescents.
I have been involved in recruiting for similar trials for very young children as old as 2 years. I am very excited about when this data gets published. At last my patients with eczema both adult and child have a brighter future with a scientifically proven new medical treatment.